Geiger Counter (GCL)

Pivot Calcs: SPX Pivot 7505---R1 7533---S1 7475---SPY Pivot 748---R1 751---S1 745----ES Pivot 7554---R1 7582---S1 7524----VIX Pivot 16.10---R1 15.67---S1 15,56---15 min Bull//Bear R/Line 16.36 !----!!LOL!!

Defiance Silver Completes Final Option Payment to Secure 100% Ownership of San AcacioJuly 8, 2026 1:00 AM
NewsfileVancouver, British Co

SCULLY ROYALTY BOARD OF DIRECTORS AND MANAGEMENT REMAIN UNCHANGEDJuly 8, 2026 1:24 AM
PR Newswire (US) Cayman Islands Court Rules Against MILFAM GroupMILFAM Group and their Purported Directors Never Held Authority to

70mil to build divided by a dollar = 70 mil dilution. Not so terrible for a real business. Paid for first year. Then zoom zoom. But a year or two wait. By then the he3 might come into play.

Rockwell Automation Announces Hadaf Foods Selects Plex Smart Manufacturing Platform to Drive Connected, Data-Driven OperationsJuly 8, 2026 1:00 AM
PR Newswire (US) UAE-based dairy manufacturer Hadaf Foods to adopt cloud-based smart manufa

Not fully sure what this means in this case

https://www.tiktok.com/t/ZP8G9fMVU/

before the Polartec announcement
OK Thank you. I'd take that. If we go to .50 and fall back again I'd OK with that. I'm done waiting around for millions of dollars that may never come.

ERCF CHANGE = F2 RELEASE

My man, was that you dumping the 30,000+ shares (I know you bought like 15,000-16,000 of them at $0,16).? 

HIRU & HW*AL's auditor izza virtual office/co-working location in Houston

https://www.tsbpa.texas.gov/wp-content/uploads/2025/08/executive_agenda_20250709.pdf

Mokuolou is reportedly here on an H15 work visa.

"The surname Mokuolu has its roots in the Yoru

Here you go again, cherry picking certain time frames to make your case. Attached is a chart of Halozyme compared to XBI since Halozyme’s IPO and also a five-year chart of Halozyme versus XBI. XBI is the purple line. I will let this board to be the judge. 
It’s not just that you were bearish

RDGL needs a marketing customer service person to replace George Sharp who sadly passed recently.
Anyone, pls pass the message to MK who must have been busy with IDE and forgotten about the vacant marketing position to be filled.

BIEL NEWS - THE MONEY IS ROLLING IN!
https://finance.yahoo.com/healthcare/articles/bioelectronics-advances-actipatch-commercial-rollout-141518246.html

Once the Buy back takes place says who?????

Conspiracy to Steal Trade Secrets and its Estimated Timeframe as well as potential insider trading.

SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment

This post is a work in progress. It contains

BIEL NEWS - THE MONEY IS ROLLING IN!
https://finance.yahoo.com/healthcare/articles/bioelectronics-advances-actipatch-commercial-rollout-141518246.html

something different

Coma (2019/2020)
This Russian sci-fi thriller follows a young architect who wakes up in a surreal, dystopian world after a mysterious car accident. He realizes this strange realm is composed of the overlapping memories and subconscious thoughts of people wh

Merveilleux ! Even if I don't know, I know that Mr. K. is and did and will do more than the necessary for KBLB to advance and be generative of fantastic products and 💲💲💲💲💲💲

Here is one I have never seen before.

https://www.klgatesdelawaredocket.com/wp-content/uploads/2016/02/ThermoplylaeCapitalvSimbol.pdf

My take on Nasrat’s answer is on the potential tariffs on the APIs to make Elite’s drugs that might affect the merger and acquisitions process.His answer is he does not think so.
However, he also did not say how tariff will affect other foreign drug manufacturers. Logically, it will and with

Valuation is difficult, should be a market cap of 20 million plus because of revs of 5.8 mil and a 3x price to revenue is almost 20 mil. Plus some gross profit with a pe of 10 would do it. But I don't know debt and current qtr numbers for the subsidiary. I wouldnt promise the moon here. Plus the wh

I want this to be better than 2021 even better than the 90’s . Let’s witness BCAP make history.